Press "Enter" to skip to content

Analysis of Oral Anti-Diabetes Drugs Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to 2024

Oral

The “Oral Anti-Diabetes Drugs Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Oral Anti-Diabetes Drugs Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Oral Anti-Diabetes Drugs market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Oral Anti-Diabetes Drugs Market Are:

  • Takeda
  • Pfizer
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • Merck And Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis
  • Sanofi

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14244768

    Market Overview:

  • The global oral anti-diabetes drug market is estimated to be USD 39.2 billion in 2019, and it is growing because of the rise in the Type 2 diabetes population.
  • Approximately 10% of diabetes cases worldwide contribute to Type 1 diabetes, and 90% of diabetes cases contribute to Type 2 diabetes.
  • The number of people who have diabetes is likely to reach 592 million by 2035. In 2013, the economic costs of diabetes across the world were estimated to be USD 548 billion.
  • Thus, the rise in prevalence of diabetes worldwide is likely to create a vast demand for diabetes drugs.

    Scope of the Report:

  • The global oral anti-diabetes drug market is segmented by drugs (biguanides, alpha-glucosidase inhibitors, dopamine-D2 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, and meglitinides) and geography.
  • A holistic study of the market has been carried out by incorporating various factors, extending from country-specific demographic conditions and business cycles to market-specific macroeconomic influences that are needed to analyze future trends. The research uncovers many paradigm shifts in the market studied, in terms of brand-level market dynamics.

    Oral Anti-Diabetes Drugs Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Oral Anti-Diabetes Drugs market?
    • What are the key market trends impacting the growth of the global Oral Anti-Diabetes Drugs market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Oral Anti-Diabetes Drugs market?
    • What are the market opportunities and threats faced by the vendors in the global Oral Anti-Diabetes Drugs market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Oral Anti-Diabetes Drugs market?

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14244768

    Key Market Trends: – DPP-4 Inhibitors Segment Has the Largest Market Share

    The DPP-4 inhibitors segment of the global oral anti-diabetes drug market was valued at USD 10,538.6 million in 2018, and it is expected to record a CAGR of 3.82% during the forecast period (2019-2024).
    DPP-4 inhibitor drugs are gaining momentum in the market because the products do not seem to have any effect on primary adverse cardiovascular outcomes and risk for heart failure.
    Besides, they can be used both as a combination therapy with insulin, sulphonylureas, and dipeptidyl peptidase-4 drugs, and as a monotherapy, thus, making it a widely used class of drugs.
    During the forecast period, the DPP-4 inhibitors segment is expected to witness constant growth rate, due to the introduction of new drugs that have improved efficacy, like glucagon-like peptide (GLP-1) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The segment is still expected to maintain the largest market share among all oral anti-diabetes drugs market segments.

    Asia Pacific leading the Oral Anti-diabetes Drugs Market

    Currently, North America holds the major share in the oral anti-diabetes drugs market. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period.
    This is due to the high prevalence of diabetes in this region, which caused consequent adverse health and economic consequences.
    Moreover, an increase in the launch of new drugs with improved efficacy and high reimbursement for medicines is expected to have a positive impact on the oral anti-diabetes drugs market.
    India, China, and Japan lead the market, due to the growing diabetes population in the Asia-Pacific region.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Oral Anti-Diabetes Drugs Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Oral Anti-Diabetes Drugs.

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/14244768

    Report Objectives:

    • Analyzing the size of the Oral Anti-Diabetes Drugs market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Oral Anti-Diabetes Drugs market.
    • Determining the key dynamics of the Oral Anti-Diabetes Drugs market.
    • Highlighting significant trends of the Oral Anti-Diabetes Drugs market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Oral Anti-Diabetes Drugs market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Oral Anti-Diabetes Drugs market.

    Detailed TOC of Oral Anti-Diabetes Drugs Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Biguanides (Value and Volume 2012-2024)
    5.1.1.1 Metformins
    5.1.2 Alpha-glucosidase inhibitors (Value and Volume 2012-2024)
    5.1.2.1 Alpha-glucosidase Inhibitors
    5.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
    5.1.3.1 Bromocriptin (Cycloset)
    5.1.4 Sodium – glucose Cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2024)
    5.1.4.1 Invokana (Canagliflozin)
    5.1.4.2 Jardiance (Empagliflozin)
    5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.4.4 Suglat (Ipragliflozin)
    5.1.5 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
    5.1.5.1 Januvia (Sitagliptin)
    5.1.5.2 Onglyza (Saxagliptin)
    5.1.5.3 Tradjenta (Linagliptin)
    5.1.5.4 Vipidia/Nesina (Alogliptin)
    5.1.5.5 Galvus (Vildagliptin)
    5.1.6 Sulfonylureas (Value and Volume 2012-2024)
    5.1.6.1 Sulfonylureas
    5.1.7 Meglitinides (Value and Volume 2012-2024)
    5.1.7.1 Meglitinides
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2 Europe
    5.2.2.1 France (Value and Volume 2012-2024)
    5.2.2.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.2 Germany (Value and Volume 2012-2024)
    5.2.2.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.4 Spain (Value and Volume 2012-2024)
    5.2.2.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.5 United Kingdom (Value and Volume 2012-2024)
    5.2.2.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.3 Latin America
    5.2.3.1 Mexico (Value and Volume 2012-2024)
    5.2.3.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.3.2 Brazil (Value and Volume 2012-2024)
    5.2.3.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.3.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4 Asia-Pacific
    5.2.4.1 Japan (Value and Volume 2012-2024)
    5.2.4.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.2 South Korea (Value and Volume 2012-2024)
    5.2.4.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.3 China (Value and Volume 2012-2024)
    5.2.4.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.4 India (Value and Volume 2012-2024)
    5.2.4.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.5 Australia (Value and Volume 2012-2024)
    5.2.4.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.6 Vietnam (Value and Volume 2012-2024)
    5.2.4.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.7 Malaysia (Value and Volume 2012-2024)
    5.2.4.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.8 Indonesia (Value and Volume 2012-2024)
    5.2.4.8.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.9 Philippines (Value and Volume 2012-2024)
    5.2.4.9.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.10 Thailand (Value and Volume 2012-2024)
    5.2.4.10.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.4.11.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5 Middle East & Africa
    5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.2 Iran (Value and Volume 2012-2024)
    5.2.5.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.3 Egypt (Value and Volume 2012-2024)
    5.2.5.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.4 Oman (Value and Volume 2012-2024)
    5.2.5.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.5 South Africa (Value and Volume 2012-2024)
    5.2.5.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
    5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

    6 MARKET INDICATORS
    6.1 Type 1 Diabetes Population (2012-2024)
    6.2 Type 2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 Company Profiles
    7.1.1 Takeda
    7.1.2 Pfizer
    7.1.3 Eli Lilly
    7.1.4 Janssen Pharmaceuticals
    7.1.5 Astellas
    7.1.6 Boehringer Ingelheim
    7.1.7 Merck And Co.
    7.1.8 AstraZeneca
    7.1.9 Bristol Myers Squibb
    7.1.10 Novartis
    7.1.11 Sanofi

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Almond Market Size 2019 By Types of Almond, Industry Growth, Demands, Restraining Factors, Growth Strategies, Sales, Revenue, and Product Analysis Till 2023

    Global Pressure and Volume Ventilation Industry Size & Share By Sales Revenue, Demands, Growth Factors, Emerging Trends, Competitive Landscape and Forecast to 2023

    Artificial Disc Replacement Market 2019 Global Overview, Latest Technologies, Business Strategy, Key Vendors, Segments, Demands, Growth Factors, Size, Share by Forecast to 2025

    Global Biobanks Market 2019 Global Industry Size, Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2024

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *